Locquet, M., Beaudart, C., Pétermans, J., Reginster, J., & Bruyère, O. (2019). EWGSOP2 Versus EWGSOP1: Impact on the Prevalence of Sarcopenia and Its Major Health Consequences.
Chicago-viite (17. p.)Locquet, Médéa, Charlotte Beaudart, Jean Pétermans, Jean‐Yves Reginster, ja Olivier Bruyère. EWGSOP2 Versus EWGSOP1: Impact on the Prevalence of Sarcopenia and Its Major Health Consequences. 2019.
MLA-viite (9. p.)Locquet, Médéa, et al. EWGSOP2 Versus EWGSOP1: Impact on the Prevalence of Sarcopenia and Its Major Health Consequences. 2019.
Varoitus: Nämä viitteet eivät aina ole täysin luotettavia.